Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

ly, Amicus announced that it had successfully completed an End of Phase 2 meeting for Amigal with the U.S. Food and Drug Administration (FDA). The FDA indicated that the data from the completed Phase 2 clinical studies of Amigal support the start of Phase 3 development and agreed that Amigal meets the criteria to be considered for accelerated approval. The Agency further indicated that it is not opposed to the use of a surrogate primary endpoint, pending further discussion and final agreement on the Phase 3 trial design.

Amicus, along with its partner Shire Human Genetic Therapies, Inc. ("Shire"), is engaged in ongoing discussions with FDA and the European Medicines Agency (EMEA) regarding plans for a global Phase 3 clinical development program for Amigal. In line with previous guidance, Amicus expects to complete these interactions in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate Phase 3 development of Amigal in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients will continue to be treated with Amigal in a voluntary Phase 2 extension study to monitor long term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected to be available by Q1 2009. In addition, Amicus expects to conduct clinical pharmacology studies to support the Phase 3 program.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, Amicus amended the protocol for the ongoing 6-month Phase 2 clinical trial of Plicera in patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009.

The Company has modified its development plan for Plicera to include a study of the pharmacokinetics of Plicera in Gaucher patients. In addit
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 NEWwoodworks, ... , is expanding their brand presence with a website ... over 20 years, NEWwoodworks has specialized in handcrafted cabinetry, ... interior furnishings. NEWwoodworks has earned a reputation for taking ... dare take on. They commonly craft with reclaimed wood, ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
(Date:7/31/2014)... 2014 The VitaSleep FDA cleared ... and provide an easier breathing capacity by slightly adjusting ... that people can breathe easier and helps reduce or ... so that it can meet the needs of each ... often shared by actual customer reviews. Johathan R. ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... 31, 2014 A program for anyone ... to the University of Colorado Anschutz Health and ... loss boot camp and transformation program. , “Extreme ... and Eyeworks USA, is an evidenced-based program inspired by ... by Eyeworks USA. This season, the show has participants ...
Breaking Medicine News(10 mins):Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3
... Blue branded dental plan,to central Pennsylvania (Lehigh Valley) ... BlueCross announced,today that it is acquiring Dominion Dental ... The move by the region,s,leading health insurer adds ... the Mid-Atlantic Region., "Helping to improve the ...
... Nov. 4 Hospira, Inc.,(NYSE: HSP ), ... announced that Christopher B. Begley, chairman and chief,executive ... Finance,and chief financial officer, will make a formal ... Conference on Wednesday, Nov. 12, 2008, in,Phoenix., ...
... PH ), the global leader in motion ... the purchase of Matrx nitrous oxide,delivery systems from ... to expand its geographic market space for dental ... American base of operations. The,product line will be ...
... Nov. 4 Allied Minds funds research to ... dermal fillers.,Allied Minds, a seed investment firm specializing ... research with Lawrence Berkeley National,Laboratory through creation of ... Eva Turley and Mina Bissell will develop a,technology ...
... of Minnesota Leverages Market Dynamics With New, Plan Offering ... ... NASHVILLE, Tenn., Nov. 4 ,HealthLeaders-InterStudy, a leading provider of managed ... the,national trend of moving from fully insured to self-insured health plans.,According ...
... Sold by A Uniquely-Trained Sales ... ... today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription for ... approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 as ...
Cached Medicine News:Health News:Capital BlueCross Acquires Dominion Dental 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 3Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:Minnesota Employers Buck National Trend and Largely Remain Fully-Insured 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: